口服普奈洛尔或内镜套扎预防肝硬化食管静脉曲张初次出血的效果观察被引量：2

Efficacy of oral administration of propranolol and endoscopic varical ligation in the prevention of ferst variceal bleeding

下载PDF

导出

摘要目的比较口服普奈洛尔与内镜套扎对肝硬化食管静脉曲张初次出血的预防效果。方法将2005-2009年间收治的96例肝硬化食管静脉曲张患者随机分成两组,每组各48例,分别单独给予口服普奈洛尔或者内镜套扎治疗,追踪随访2年,比较两组的出血率、病死率、并发症发生率的情况。结果普奈洛尔组与内镜套扎组的出血率分别为22.2%、25.0%;病死率为42.2%、40.1%;与出血相关病死率为15.6%、11.4%;并发症发生率为11.1%、13.6%;两者比较差异均无统计学意义(P>0.05)。结论有高危出血因素而无出血史的中重度食管静脉曲张肝硬化患者应首选非选择性β受体阻滞剂预防首次静脉曲张出血,不适用者可选用内镜套扎。 Objective To compare the efficacy of medical therapy （propranolol） and endoscopic varical li- gation （EVL） in the prevention of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Methods Ninety-six cirrhotic patients with high-risk esophageal varices admitted in our hospital from 2005 to 2009 were divided into two groups and treated with oral administration of propranolol （propranolol group, n--48） or EVL （EVL group, n--48）, respectively. The patients were followed up for two years. The bleeding, complications and mor- tality were compared between the two groups. Results The rate of bleeding, mortality rate, bleeding-related mortality rate, incidence of complications were 22.2%, 42.2%, 15.6%, 11.1% in propranolol group, and 25.0%, 40.1%, 11.4%, 13.6% in EVL group, respectively. There is no statistically significant difference between the two groups （P〉0.05）. Conclusion The cirrhotic patients who have high risk factors and no history of variceal bleeding should first take medical therapy （propranolol） for preventing first variceal bleeding. If not, they can select endoscopic varical ligation.

作者陈慧婷聂玉强

机构地区广州医学院附属广州市第一人民医院消化内科

出处《海南医学》 CAS 2013年第15期2289-2291,共3页 Hainan Medical Journal

关键词内镜套扎普奈洛尔食管静脉曲张出血 Endoscopic variceal ligation Propranolol Esophageal variceal Bleeding

分类号 R575.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献14

1Chang YW. Indication of treatment for esophageal varices: who and when?[J]. Dig Endosc, 2006, 18(1): 10-15.
2De Franchis R. Updating consensus in portal hypertension: report of the Baweno ill Consensus Workshop on definitions, methodology and therapeutic strategier in portal hypertension[J]. J Hepatol, 2000, 33(5): 846-852.
3Garcia-Tsao G. Portal hypertensioa[J]. Curr Opin Gastroenterol, 2003, 19(3): 250-258.
4Abraczinskas DR, Ookubo R, Grace NO, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime com?mitment[J]. Hepatology, 2001, 34(6): 1096.
5Arguedas MR, Heudebert GR, Eloubeidi MA, et al. Cost-effective?ness of screening, surveillance, and primary prophylaxis strategies for esophageal varices[J]. Arne J Gastroentrology, 2002, 97(9): 2441.
6D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of por?tal hypertension: an evidence-based approach[J]. Semin Liver Dis, 1999, 19: 475-505.
7Harry R, Wendon J. Management of variceal bleeding[J]. Curr Opin Crit Care, 2002, 8(2): 164-170.
8Lay CS, Tsai Y, Teg C, et al. Endoscopic variceal ligation in prophy?laxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices[J]. Hepatology, 1997,25: 1346-1350.
9Lo GH, Lai KH, Cheng JS, et al. Prophylactic banding ligation of high risk esophageal varices in patients with cirrhosis: aprospective, randomized trial[J]. J Hepatol, 1999,31: 451- 456.
10Imperiale T, Chalasani N. A meta-analysis of endoscopic variceal li?gation for primary prophylaxis of esophageal variceal bleeding[J]. Hepatology, 2001, 33: 802- 807.